The pandemic pressure-tested several key commercial shifts that pharma has been talking about for years. James Anderson and Bruce Carlson reflect on what we’ve learned about the future of HCP engagement for Bio-IT world. Read the full article here.
By empowering leaner teams to reach HCPs more efficiently, AI is set to be the great commercial equalizer for emerging and mid-sized pharma. James Anderson breaks down how AI can help SMB organizations thrive in a dynamic market for Coruzant Technologies. Read the full article here.
On the other side of the pandemic lies a new era of innovation for the life sciences industry—especially when it comes to HCP engagement. Aktana’s James Anderson shares five key takeaways for using AI to transform commercial execution with MedCity News. Read the full article here.
From remote engagement to AI-driven personalization, COVID’s impact on the pharma industry will be felt long after the pandemic subsides. Jay Borowiecki and other industry leaders predict which changes will fade and which will redefine the way we engage with HCPs for MedAdNews. Read the full article here.
Aktana’s Derek Choy joins leaders from Veeva, Salesforce, Antares and Monocl to break down how life sciences commercial teams are adapting to the digital shift accelerated by the pandemic. Read more from MM+M here
Understanding the “why” behind any recommendation is critical for adoption. In the December issue of Pharmaceutical-commerce, Derek Choy breaks down how explainable AI provides the context users need to trust AI and bring about true commercial transformation. Read the full article here.
We’re thrilled to be recognized with an Innovations Award from PM360 for our Contextual Intelligence Engine, which learns from every interaction to help sales, marketing and field medical teams coordinate more personalized, meaningful omnichannel engagements with HCPs. Established in 2011, the Annual PM360 Innovations Issue highlights the most exciting advancements that are helping to push […]
PharmaVOICE asked Derek Choy and other industry thought leaders how the role of AI in the life sciences will expand and evolve in 2021. Read their predictions for the new year here.
More information means more potential for personalization, but only if commercial teams can extract the right context to orchestrate meaningful HCP interactions at scale. Derek Choy tells PM360 how the next generation of AI tools have evolved to do just that. Read the full article here.
“AI 2.0 is here, and it’s helping companies deepen HCP engagement in a digitally driven commercial model.” Aktana’s co-founder and president, Derek Choy, explains how the next generation of AI uses context to create human experience in a digital-first world. Read the full article here.